PDE5A and systemic sclerosis: Digital Ulcers: Other vasoactive agents recommended for the treatment of SSc-RP and DUs, such as PDE-5 inhibitors, intravenous iloprost, fluoxetine, and bosentan, are either unavailable or not approved for these indications by the Republic Health Insurance Fund in Serbia.